About Caladrius

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases.

News

June 19, 2018
Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina

June 5, 2018
Caladrius Biosciences Sells Rights to Counter-Flow Centrifugation System to Hitachi Chemical Advanced Therapeutics Solutions

May 10, 2018
Caladrius Biosciences Reports 2018 First Quarter Financial Results

Events

May 10, 2018
First Quarter 2018 Financial Results Call

April 26, 2018
Fourth International Vatican Conference

April 12, 2018
GTCbio 15th Stem Cell Summit

Sign up to our e-mail list to receive Caladrius announcements.

Technologies & Capabilities

T Regulatory Cell Technology

T Regulatory Cell Technology

CD34 Cell Technology

CD34 Cell Technology